Advertisements


Roche drug cocktail doubles chance of halting lung cancer

Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts on Thursday labeled unprecedented......»»

Category: topSource: foxnewsDec 7th, 2017

Roche drug cocktail doubles chance of holding lung cancer at bay

Roche's November announcement that its Impower 150 trial had broadly succeeded in first-line lung cancer patients.....»»

Category: topSource: business-standardDec 7th, 2017

This New Drug Combination Doubles the Chance of Keeping Lung Cancer at Bay

The finding could result in annual sales of $4.6 billion by 2023. Adding Roche’s rhhvf immunotherap.....»»

Category: europeSource: fortuneDec 7th, 2017

Roche"s Lung Cancer Drug Alecensa Meets Primary Endpoint

Zacks.....»»

Category: topSource: redinewsApr 10th, 2017

Roche"s Lung Cancer Drug Alecensa Meets Primary Endpoint

Roche (RHHBY) announced that the global.....»»

Category: topSource: zacksApr 10th, 2017

Roche Announces Positive Data on Lung Cancer Drug Alecensa

Roche Holdings AG (RHHBY) recently announced encouraging results from the phase III study, ALUR on lung cancer drug Alecensa. Roche Holdings AG RHHBY recently announced encouraging results from the phase III study, ALUR on l.....»»

Category: topSource: zacksApr 5th, 2017

Roche Announces Positive Data on Lung Cancer Drug Alecensa

Zacks.....»»

Category: topSource: redinewsApr 5th, 2017

A drug that uses the immune system to fight cancer cells just got approved for lung cancer (RHHBY, BMY, MRK)

Thomson Reuters(Reuters) - Swiss drugmaker Roche Holding AG's new immunotherapy, Tecentriq, won approval on Tuesday from U.S. health regulators as a second-line lung cancer treatment, a decision seen likely to erode Bristol-Myers Squibb's position in this.....»»

Category: topSource: businessinsiderOct 19th, 2016

FDA Approves Genentech"s Lung Cancer Drug

Roche Group's Genentech said late Tuesday the Food and Drug Administration has approved its Tecentriq immunotherapy medicine for the treatment of certain types of lung cancer......»»

Category: topSource: foxnewsOct 18th, 2016

FDA approves Genentech"s lung cancer drug

Roche Group's Genentech said late Tuesday the Food and Drug Administration has approved its Tecentriq immunotherapy medicine for the treatment of certain types of lung cancer. Tecentriq may treat lung cancer by working with the immune system and targetin.....»»

Category: topSource: marketwatchOct 18th, 2016

Roche Alecensa Wins Second Breakthrough Status in the U.S.

Roche (RHHBY) announced that the FDA has granted a second breakthrough therapy designation for Alecensa. Roche Holding AG RHHBY announced that its lung cancer drug, Alecensa, was granted a second breakthrough therapy designation in the U.S. for.....»»

Category: topSource: zacksOct 4th, 2016

AstraZeneca"s immunotherapy drug gets US FDA nod for lung cancer treatment

US FDA granted approval for expanded use of Imfinzi to treat non-small cell lung cancer patients.....»»

Category: topSource: business-standard22 hr. 9 min. ago

Biotech Analysis Central Pharma News: Bristol-Myers Squibb"s Push On Lung Cancer, EyeGate"s Blow Up, Roche"s Advance In Kidney Cancer

Biotech Analysis Central Pharma News: Bristol-Myers Squibb"s Push On Lung Cancer, EyeGate"s Blow Up, Roche"s Advance In Kidney Cancer.....»»

Category: topSource: seekingalphaFeb 6th, 2018

Bristol-Myers surges 5.6% on advanced lung cancer trial results, Q4 earnings

Bristol-Myers Squibb Co. shares surged 5.6% in premarket trade on Monday after the company reported positive results for its Opdivo and Yervoy cancer drug combination in a lat.....»»

Category: topSource: marketwatchFeb 5th, 2018

Amgen/Allergan"s Avastin Biosimilar Secures EU Approval

Amgen (AMGN) and Allergan's Mvasi - a biosimilar version of Roche's cancer drug, Avastin - gets marketing approval in the EU. Amgen, Inc. AMGN and partner Allergan AGN announced that the European Commission has granted marketin.....»»

Category: dealsSource: nytJan 19th, 2018

Merck & Co., Inc. (MRK) Stock Surges on Lung Cancer Drug Success

InvestorPlace - Stock Market News, Stock Advice & .....»»

Category: topSource: investorplaceJan 17th, 2018

Brainstorm Health: Universal Flu Vaccine, Merck Lung Cancer Drug, UnitedHealth Earnings

Brainstorm Health Daily: January 16, 2018 Hello, readers! This is Sy. Google parent Alphabet’s venture arm GV (formerly Google Ventures) is among the companies backing U.K. biotech Vaccitech, which has set out to achieve one.....»»

Category: europeSource: fortuneJan 16th, 2018

Merck leaps past rivals with latest lung cancer drug results

Smoking, which causes many lung cancer cases, has made advanced lung cancer a big market for pharmaceutical companies, and the competition has been fierce......»»

Category: topSource: marketwatchJan 16th, 2018

UPDATE: Merck shares jump 7% on news of positive results from lung cancer trial

Merck & Co. Inc. shares jumped almost 7% Tuesday, after the company announced positive results in a late-stage lung cancer trial. The New Jersey-based drug company said the Phase 3 trial of Keytruda in combination with pemetrexed and cisp.....»»

Category: topSource: marketwatchJan 16th, 2018

Merck Wins Big With Late-Stage Lung Cancer Drug Results

Merck saw its shares make a handy gain on Tuesday after it reported that a late-stage trial of Keytruda met its dual primary endpoints......»»

Category: blogSource: 247wallstJan 16th, 2018

UPDATE: Merck shares jump 5% on news of positive results from lung cancer trial

Merck & Co. Inc. shares jumped 5% premarket Tuesday, after the company announced positive results in a late-stage lung cancer trial. The New Jersey-based drug.....»»

Category: topSource: marketwatchJan 16th, 2018